跳到正文
原文
The Lancet· Shaodong Hong, Ting Zhou, Xue Hou, Xiangjiao Meng, Zhihuang Hu, Wei Zheng, Jiuwei Cui, Yongzhong Luo, Lin Wu, Meijuan Huang, Haipeng Xu, Jie Hu, Yanqiu Zhao, Wenxiu Yao, Yonggui Hong, Jun Cai, Yu Zhang, Chunxia Su, Conghua Xie, Ruoyu Wang, Xiang Li, Qiong He, Liang Zhang, Ruiling Ning, Daren Lin, Tongmei Zhang, Tienan Yi, Liqiang Zhong, Siyuan Huang, Hui Zhao, Jian Fang, Qing Bu, Bihui Li, Zhiye Zhang, Meiqi Shi, Jianhua Shi, Zhiping Deng, Yi Zhu, Hai Zhu, Sa Xiao, Lei Yang, Ni Song, Wenfeng Fang, Li Zhang, Yunpeng Yang, PANKU-Lung01 Investigators·· 25 天前精选AI 评分82

PANKU-Lung01 III 期试验:iza-bren 对比含铂化疗延长 EGFR 突变晚期非鳞 NSCLC 患者 PFS

[Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

AI 导读

PANKU-Lung01 是一项在中国开展的多中心、随机、开放标签 III 期试验,比较 izalontamab brengitecan(iza-bren)与含铂化疗用于三代 EGFR TKI 进展后的 EGFR 突变晚期非鳞 NSCLC 患者。

推荐理由

这项中国多中心 III 期试验为 EGFR 突变 NSCLC 三代 TKI 耐药后人群提供了双特异性 ADC 的对照数据。

来源:The Lancet · thelancet.com